The research shows overwhelmingly that when Mounjaro is used as a monotherapy or with only Metformin, the risk of having dangerous lows are very minimal, particularly compared to taking insulin or a sulfonylurea drug.
This is because it only stimulates insulin secretion from the pancreas in the presence of a hyperglycemic (high blood sugar) state. The GIP receptor agonist in Mounjaro also stimulates the secretion of glucagon from the liver in the presence of a hypoglycemic (low blood sugar) state and this reduces the occurrence of hypoglycemia (blood sugar lows).